Menu
ETF
Annual · values2025202420232022202120202019
Operating Cash Flow-94.72 M USD-87.80 M USD-94.04 M USD-90.56 M USD-66.81 M USD-32.57 M USD-30.71 M USD
Depreciation & Amortization4.45 M USD4.60 M USD4.16 M USD2.58 M USD1.04 M USD894000 USD780000 USD
Stock-Based Compensation10.77 M USD8.89 M USD8.52 M USD11.21 M USD24.92 M USD1.92 M USD2.71 M USD
Capital Expenditures2.52 M USD4.58 M USD4.51 M USD10.74 M USD5.76 M USD461000 USD1.24 M USD
Cash Flow from Investing-28.32 M USD-32.67 M USD143.43 M USD137.19 M USD-450.94 M USD-461000 USD-1.24 M USD
Cash Flow from Financing95.42 M USD35.88 M USD149000 USD1.91 M USD516.63 M USD37.01 M USD18.22 M USD
Dividends Paid
Stock Buybacks
Free Cash Flow-97.23 M USD-92.38 M USD-98.55 M USD-101.30 M USD-72.58 M USD-33.03 M USD-31.95 M USD

Quantum-Si Incorporated is a life sciences company pioneering next-generation protein sequencing (NGPS) through its proprietary single-molecule detection platform. This technology enables researchers to sequence proteins at the single amino acid level, providing unprecedented insights into proteomics for applications such as antibody characterization, biomarker identification, protein variant analysis, and post-translational modification studies. The company's flagship products include the Platinum and Platinum Pro NGPS instruments, which offer streamlined workflows, automated data analysis, enhanced user interfaces, and options for cloud or on-instrument processing, making advanced protein analysis accessible to labs of all types. Complementary consumables encompass Library Preparation Kits, Barcoding Kits, and Sequencing Kits, along with Platinum Analysis Software for intuitive visualization and workflow automation. By merging semiconductor technology, biology, chemistry, and artificial intelligence, Quantum-Si Incorporated advances the post-genomic era, empowering breakthroughs in drug discovery and diagnostics. Founded in 2013 and headquartered in Branford, Connecticut, it focuses on revolutionizing protein research worldwide.